We have used W"/w' (C57BLIS-Ly 5.1, Gpi-lb) anemic mice and a newly developed double congenic donor strain (C57BLlGLy 5.2, Gpi-l') to determine if adult bone marrow (BM) injected in utero could provide stem cell engraftment. Of 38 fetuses injected intraperitoneally on day 13/14 of gestation with donor BM cells, 17 (47%) were live-born. On day 6,12% had erythroid engraftment. On day 59, in 50% (8/16) of mice, 50% to 75% of erythroid cells, 42% of T cells, 5% of B cells, and 26% of granulocytes in the peripheral blood (PB) were derived from the in utero-injected donor BM. At 141 NTRAUTERINE bone marrow transplantation is a relatively new transplant procedure that has been used to treat some types of human heritable disorders.' The intent of this therapy is to replace missing or defective cell lineages or enzymes with lifelong hematopoietic cells. To ensure long-term reconstitution, hematopoietic stem cells (HSCs) must engraft to provide a permanent source of erythroid, myeloid, lymphoid, and megakaryocytic lineages. It is, therefore, essential to determine if congeneic or allogeneic HSCs, which would be the likely sources of HSCs for in utero transplantation, are indeed engraftable in utero.
NTRAUTERINE bone marrow transplantation is a relatively new transplant procedure that has been used to treat some types of human heritable disorders. ' The intent of this therapy is to replace missing or defective cell lineages or enzymes with lifelong hematopoietic cells. To ensure long-term reconstitution, hematopoietic stem cells (HSCs) must engraft to provide a permanent source of erythroid, myeloid, lymphoid, and megakaryocytic lineages. It is, therefore, essential to determine if congeneic or allogeneic HSCs, which would be the likely sources of HSCs for in utero transplantation, are indeed engraftable in utero.
Zanjani et a12 have shown that xenogeneic HSCs (human fetal liver cells) are capable of providing persistent postnatal multilineage repopulation when injected into preimmune fetal sheep. While the sheep studies address the issue of HSC engraftment in vivo and provide important information as to the engraftability of human progenitor cell populations in utero in sheep, xenogeneic HSCs are not currently used to correct human hereditary disease, and there are few sheep that have the manifestations of the hereditary disorders that are the targets of human in utero transplantation. In contrast with sheep, mice, while technically difficult to access for in utero transplantation, are highly useful for providing direct evidence as to the feasibility of using in utero transplantation for correcting certain types of human hereditary diseases. A number of strains of mice have been identified that have well-defined, naturally occumng, inherited disorders involving the hematopoietic: immune:
or enzymatic' systems. In the absence of naturally occurring genetic mutations or deletions, mice can be altered by recombinant DNA technology, to have genetic deficiencies that share the characteristics of their human Therefore, the question as to whether HSCs can engraft in murine fetal recipients in utero is critical to determining the usefulness of mice as preclinical model systems for in utero correction of hereditary disorders. No studies to date have formally demonstrated that syngeneic, congeneic, or allogeneic HSCs are engraftable. The most suggestive data are those of Fleishman and Mintz,I3.l4 who used W locus mutant fetal recipients that have an endogenous stem cell defect due to a mutation in c-kit, a tyrosine kinase receptor that binds a ligand (kit ligand) that stimulates the expansion of cells with multipotential capacity. They reported that 10 of 23 (43%) evaluable W/W mice were engraftable for 2 6 months with either fetal liver (four of six, 67%)13 or bone showing that HSCs from a host undergoing in utero transplantation can be adoptively transferred to a secondary recipient.
To demonstrate in utero stem cell engraftment, we developed a new murine in utero model system with three unique advantages over previously described experiments. First, two types of C57BLl6 congeneic mice were backcrossed and intercrossed to obtain homozygous donors expressing both the Ly 5 (CD45, panhematopoietic marker) allele, Ly 5.2, and the glucose-phosphate isomerase (Gpi) allele, 1". Thus, when c57BLl6-L~ 5.1, Gpi-lb recipients were transplanted with donor bone marrow (BM), mice could be monitored postnatally for erythroid engraftment by the Gpi allele as early as day 5 and later for leukocyte engraftment in the various lineages by the Ly 5 allele. Second, we chose C57BU6-W4'/W4' (termed W4'/W4') mice as fetal recipients." These mice have a moderate anemia due to a different mutation in c-kit than the more severely anemic W/W or W W mice." However, the anemia is sufficiently mild that fertility is not compromised. These data show for the first time that murine congeneic adult BM-derived HSCs are engraftable by in utero transfer into murine fetal recipients with an endogenous HSC defect.
MATERIALS AND METHODS
Mouse strain.\. W4'/W4' mice (identical to C57BL/6 except for a mutation at the W locus) were obtained from Drs Jane Barker and Leonard Shultz (Jackson Laboratories, Bar Harbor, ME). C57BL/6-Ly 5.2+, Gpi-l" (H-2b, Gpi-l") mice were bred in our mouse colony by mating C57BL/6-Ly 5.2' Gpi-lh mice with C57BL/6-Ly 5.1+
Gpi-l a mice. Progeny were screened by Gpi typing for Gpi-I" expression and by flow cytometry for Ly 5.2 expression. Obligate heterozygotes were intercrossed to generate the desired homozygotes, which were doubly congeneic.
Timed pregnancies. Male breeders were housed individually in microisolator cages in a specific pathogen-free facility. Two females were placed in the cage for 2 days to mate. The pairs were then separated. Day 0 of gestation was the day the females were separated from the males. Average gestation was about 20 to 21 days.
Intraperitoneul microinjections.
Bone marrow cells were harvested from 6-to 12-week-old donors by flushing cells from the hind leg bones with phosphate-buffered saline (PBS). Cells were filtered through nylon mesh (Nitex HC3-41; Tetko, Chicago, IL) to remove clumps before injection. Cells were adjusted to 1.5 X 10' concentration in 3 pL media before injections. Pregnant females were anesthetized with sodium pentobarbital injected IP. The abdomen was entered with a midline ventral approach, and the uterine horns were exteriorized with jeweller's forceps. Cells were injected 1P through a Hamilton model 7 I O repeating syringe (Hamilton CO, Reno, NV) with 33-gauge needles. The muscle layers were closed with nonabsorbable synthetic 4-0 sutures, and metal surgical clips were used to close the skin.
Assessment ofengraftmenr. Peripheral blood (PB) from all liveborn mice was screened at periodic intervals by Gpi typingrh and flow cytometry17 for evidence of in utero engraftment. Heparinized PB from adult mice was obtained by retroorbital venipuncture under ether anesthesia. For Gpi typing to determine erythroid engraftment, whole blood lysates were used. For PB flow cytornetry to determine T-cell, B-cell, and myeloid engraftment, the blood was diluted in 3 mL of media and layered on ficoll (Histopaque 1 1 19 ; Sigma, St Louis, MO), and the samples were centrifuged at 600g for 30 minutes.
Gpi typing. PB was obtained from recipient mice on postnatal day 6 by toe amputation. A droplet of blood was collected on a piece of chromatography paper (Whatman 3030917; Hillsboro, OR). Whole blood was frozen at -20°C until analysis. The donor or recipient origin of the Gpi-l was assessed using starch gel electrophoresis followed by transfer of whole blood lysates onto nylon membranes and staining for Gpi isoenzymes as previously described."
Flow cytometry. PB cells or single-cell suspensions of' BM, spleen, lymph node, or thymus were prepared in buffer (PBS plus 5% colostrum-free bovine serum plus 0.015% sodium azide). Pelleted cells were incubated for 15 minutes at 4°C with 0.4 pg of an anti-Fc receptor monoclonal antibody (MoAb; clone 2.462, provided by Dr Jay Unkless, Rockfeller University, New York, NY) to prevent Fc binding.IR Two-color flow cytometry was performed using directly conjugated (fluoroscein isothyocyanate or biotin) MoAbs as previously described." Optimal concentrations of directly conjugated MoAbs were added to a total volume of 100 to 130 pL and incubated l hour at 4°C. For biotin-labeled MoAb, fluorescence was indirectly measured by adding streptavidin-labeled Red 61 3 (GIBCO BRL, Gaithersburg, MD) for an additional 1 hour at 4°C. After final washing, cells were fixed in I % paraformaldehyde. Two-color flow cytometry was performed using directly conjugated (fluoroscein isothyocyanate or biotin and streptavidin-phycoerythrin) anti-Ly 5. 1 -specific and anti-Ly 5.2-specific MoAbs (rat IgG2a, provided by Dr Ule Hammerling, Memorial Sloan-Kettering Cancer Research Center, New York, NY) and the following lineage-specific antibodies obtained from PharMingen (San Diego, CA): anti-CD3 (145-2C1 I , hamster IgG), anti-CD4 (GK1.5, rat IgG2b), anti-CD8 (53-6.7, rat IgG2a), pan-B cell (B220: Ra3-6B2, rat lgG2a), CD69 (clone HI .2F3, hamster IgG), and pan-granulocyte (Rb6-8C5, rat IgG2b).
All samples were analyzed on a FACscan (Becton Dickinson, Palo Alto, CA) using Consort-30 software. Forward and 90" sidescatter were used to identify and gate PB cells with lymphocyte, monocyte, and granulocyte characteristics. A minimum of 10,000 events were examined. Background subtraction using a directly conjugated irrelevant antibody control was performed for each sample as previously described.'? Secondary transfer experimerats. Nonmanipulated adult BM, obtained from long-term chimeras that had been engrafted in utero at least 5 months earlier using adult BM cells as a source of HSCs. was used to repopulate lethally irradiated [9.0 Gy total body irradiation (TBI), delivered by x-ray at a dose rate of 0.45 Gy/min as previously described"], nonanemic C57BL!6 recipients. BM from individual donors was administered via tail vein at a cell dose of 3.5 x IO6 per recipient to each of 5 to I O secondary recipients.
Post-bone marrow transplant (BMT), these mice were analyzed for engraftment as discussed above.
RESULTS

Successful long-term postnatal engrafrment of adult BM when tramferred in utero into moderately anemic,fetal mice.
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From W"M" (C57BU6-Ly5.1'/Gpi-lb) moderately anemic fetal mice were injected on day 13/14 of gestation with nonenriched adult BM (1.5 x lo6 cells) from double congeneic C57BU6-Ly5.2/Gpi-la mice. Engraftment was determined by Gpi typing of PB as described in Materials and Methods. Because of the high proportion of erythroid cells in PB, these data reflect erythroid engraftment only. Days 59 through 141, which include day 95, are listed together as engraftment stabilized at these times. A ninth engrafted mouse had intermittent evidence of donor erythroid cells during the later time periods of analysis. This mouse is not included in the table because the engraftment was at a low level that was not consistently demonstrable by Gpi typing.
In a series of IP injected day 13/14 gestational fetuses, we observed a 47% (17 of 38) live-birth rate. Gpi typing was performed at eight different postnatal intervals (Table I ). On day 6, only 2 of 17 (12%) had clear evidence of erythroid engraftment. The incidence of engraftment rapidly increased, with 4 of 17 (24%) engrafted by day 15 and 7 of 17 (41 %) on day 20. In the first 39 days, a minority of cells was positive for donor engraftment by Gpi typing (range, 5% to less than 50%). All engrafted mice analyzed at 59 days or later showed erythroid engraftment in the range of 50% to 75% donor cells (Fig l) . Engraftment was stable for the remaining period of observation.
Flow cytometry of PB was used to assess the level of donor cell engraftment in nonerythroid lineage cells. Of the eight mice with easily demonstrable day 39 donor erythroid engraftment, all had concurrent engraftment in nonerythroid lineages (Table 2) . When examining the individual lineages for the proportion of donor cells on day 39 postnatally, the mean donor cell values in engrafted mice as determined by Ly5 typing of gated PB cell fractions, were 4% for lymphocytes, 6% for myeloid cells, and 2% for monocytes. The level of engraftment in each mouse was stable or increased over time (especially T-cell and myeloid engraftment; Table  2 ). The highest levels of engraftment were observed in the T-cell lineage, followed by granulocytes and then B cells. Also, four of eight engrafted mice studied at the latest time period (day 141) had greater than 15% donor PB cells (range, 16% to 33%), which should be sufficient for the correction 1 2 3 4 5 of some types of hereditable disorders, whereas the remaining four mice had lower levels of donor PB cells. In these same four mice, a majority of the CD4' (54% to 7 I %) and CD8' (50% to 63%) T cells were of donor origin. In addition, 33% to 50% of PB myeloid cells were of donor origin in the four mice with the highest levels of engraftment.
Multilineage postnatal engrqjiment of ~~d u l t BM when transferred in utero into moderately anemic .fetal mice.
Two mice with the highest levels of PB leukocyte engraftment (32% and 33% donor cells) on postnatal day 141 were killed on day 150 to assess multiorgan system engraftment (Table 3) . because it is possible that the in utero injection of adult BM may preferentially reside in the organs and not the PB. The level of thymic and extrathymic T-cell engraftment was high in all peripheral lymphoid organs. The proportion of T cells that were donor-derived ranged from 57% to 7 1 %, which was higher than the proportion of donorderived B cells (range, 10% to 20%). The high level of Tcell engraftment was also reflected in analysis of the thymus. Consistent with the peripheral lymphoid engraftment data, the most mature thymocytes (single positive: CD4'8-or CD4-8') were exclusively of donor origin, while CD3' or CD69' (an activation antigen expressed on thymocytes as these cells enter their final stage of maturation'") cells, which could be either mature single or double positive cells, were predominately (266%) of donor origin. The fact that peripheral lymphoid engraftment was reflective of thymic engraftment indicates that the mature T cells can peripheralize Gpi typing of postnatal day 141 PB in W"/W" fetal recipients that received a single injection of 1.5 x 10' adult BM in 4 p L given on day 13 of gestation. Each lane represents blood from an individual mouse. The Gpi-lb allele represents the normal C57BL/6 type, while the Gpi-l' allele represents the presence of C57BLbLy 5.2/Gpi-l' material. There is a band intermediate in size between the Gpi-l' and the Gpilb alleles that may represent complexes between the Gpi-l' and Gpi-lb alleles. The first five lanes represent mixtures of W"/W" (Gpi-lb) and C57BL/bLy 5.2/Gpi-l" material in proportions of 1%/99%, 5%/95%, 10%/90%, 25%/75%, and 50%/50% (lanes 1 through 5, respectively W"/W" (C57BL/6-Ly5.1+/Gpi-lb) moderately anemic fetal mice were injected on day 13/14 of gestation with nonenriched adult BM (1.5 x 10' cells) from double congeneic C57BU6-Ly5.2+/Gpi-la mice. Engraftment was determined by PB flow cytometry as described in Materials and Methods. Values have been normalized such that Ly 5.2' donor and Ly 5.1' recipient cells total 100% for that cell population. At all time periods, the PB consisted of approximately 50% to 56% 8220' B cells, 18% to 25% CD4' T cells, 8% to 10% CD8' T cells, and 8% to 10% gran-l+ myeloid cells.
Postnatal day 60
Postnatal day 95* Postnatal day 141* Abbreviations: ND, not determined; NA, not analyzable.
* PB was not further analyzed using lineage-specific fluorochromes.
t The T-cell compartment was assessed by combining anti-CD4 and anti-CD8 antibodies without attempt to distinguish CD4+ v CD8' T cells. * An additional mouse had evidence of engraftment at these two time periods, with 2% to 5% of each lineage comprised of donor cells. This ninth engrafted mouse had evidence of erythroid engraftment that was intermittently demonstrable by Gpi typing. There was no evidence of donor cells when this mouse was reanalyzed on postnatal day 193. The data are not represented in Table 2 , which focuses exclusively on the eight consistently engrafted mice described also in Table 1 and home to the appropriate end-organ. Donor cells repopulated the myeloid compartment at an intermediate level, with 27% to 43% of myeloid cells being of donor origin as compared with the T-cell or B-cell lineages. The proportions of donor myeloid cells in the PB, spleen, and BM were similar. Both mice had higher hematocrit values at the time of death than nontransplanted W4'/W4' mice, but lower values than nonanemic C57BL/6 mice (48% and 47% v 44% v 51%, respectively). These two mice were used as donors for secondary transfer studies (see below).
Seven additional mice were killed on postnatal days 227 or 233 for multiorgan system engraftment typing as described in Table 3 . The proportions of PB cells that were donor-derived as measured on day 193 in the individual mice were 32%, 13%, 12%, 5%, 2%, s l % , and 0% (data not shown). The recipient that had no evidence of PB engraftment on day 193 also had no evidence of donor cells of the various lineages in the spleen, lymph node, BM, or thymus. All mice with PB engraftment on day 193 also had donor cells in each of the organs studied. In individual mice, the level of T-cell and B-cell engraftment in the peripheral lymphoid organs (PB, spleen, lymph node) was highly correlated, as was myeloid engraftment in the medullary (BM) and extramedullary (PB, spleen) organs (data not shown). In five of seven mice, the level of T-cell engraftment at each stage of thymic differentiation also correlated with that of the peripheral lymphoid organs, while in the other two, thymic engraftment was either substantially lower (n = 1) or higher (n = 1) than observed in the periphery.
Adult BM stem-ceiL engrafhnent, assessed by transferring BM from engrafted primary recipients into lethally irradiated secondary recipients, can be achieved in utero. The long-term (greater than 5 months postinjection) multilineage organ system engraftment data suggest but do not prove that stem-cell engraftment has been achieved in utero. To prove that stem-cell engraftment has been achieved, we transferred BM (3.5 X lo6 cells per secondary recipient) from these two mice into lethally irradiated C57Bw6-L~ 5.1' Gpi-lb (n = 5 for each donor) secondary recipients. Because the original donor BM progenitor source was c57BLl6-L~ 5.2/Gpi-la, donor cells from the in utero BM source could be distinguished in these secondary recipients.
Mice were bled at periodic intervals, beginning on day 14 after secondary transplant, for engraftment analysis. Gpi gels in seven of nine mice evaluable on day 14 showed evidence of the original in utero donor progenitor cells, with values ranging from 5% to 25% and with most recipients having 10% to 20% donor cells. By the time of the next analysis (day 41 post-BMT), all recipients had erythroid engraftment ranging from 50% to 75% donor cells (Table 4, Fig 2) . Two-color flow cytometric analysis of the PB of these mice showed that 10% to 16% of the PB in the secondary recipients was derived from the original adult BM source used to reconstitute W4'/W4' fetal recipients in utero (Table 5) . Tcell, B-cell, and granulocyte lineages were all partially comprised of cells derived from the in utero donor BM source. The mean levels of B-cell and granulocyte engraftment in the secondary recipients closely reflected the levels observed in the primary recipients on the day of death (Table 3) . AS compared with the primary recipients analyzed on the day of death, the proportion of T cells that was derived from the initial in utero donor BM appeared to be lower, with mean For personal use only. on October 27, 2017. by guest www.bloodjournal.org From No. engraftedlno. 5 x 1 0 ' cells) , obtained from two mice with the highest levels of engraftment as assessed by day 141 PB typing, was transfered into lethally irradiated secondary recipients (n = 5 recipients for each donor). Gpi typing was performed to assess erythroid engraftment. The overall incidence and range of engraftment was similar in each of the secondary recipients, regardless of which donor BM these mice received. Therefore, the data are shown together for all secondary recipients. recipients of BM from each donor are shown in Table 6 . Donor l had similar levels of engraftment as compared with the previously described donors in the secondary transfer experiment in Table 3 . The levels of PB B-cell and myeloid donor cell engraftment on day 58 post-BMT (Table 6) were consistent with the aforementioned day 65 engraftment values shown in Table 3 . The proportion of PB CD4' and CD8+ T cells that were derived from the in utero transplanted donor BM was lower than previously observed (for CD4+ T cells, 11.8% v 18.8%; for CD8+ T cells, 12.5% v 29.8%, respectively, derived from the in utero donor BM), despite the fact that central and peripheral T-cell engraftment in the primary recipients was similar when comparing the previous two postnatal donors to the current donor at the time of sacrifice (Table  3 and data not shown). In studies using donor 2, the PB engraftment in the secondary recipients was only marginally lower overall, although the proportions of PB B cells and CD4+ T cells that were of in utero donor BM origin were reduced by 50% to 60% as compared with the level observed when using donor I (Table 6) , consistent with the lower proportion of donor cells in the BM inocula used for secondary reconstitution. On day 96 posttransfer, the level of engraftment was higher in each lineage for donor 1 but fluctuated for donor 2. Cumulatively, in the two sets of experiments, all 29 of the evaluable secondary recipients had evidence of donor cells derived from the original in utero BM transfer. These data document the capacity of adult BM stem cells to engraft in utero in midgestational fetal recipients.
Range of donor cells (%)
DISCUSSION
The major finding of this study is that congeneic pluripotent HSCs can be engrafted in utero when injected IP into Fig l) , and lanes 9 through 12 are from the second donor (lane 16, Fig 1) . Engraftment is evident in each lane.
WJ'/WJ' fetal recipients. Our studies have extended those of Fleishman and Mintz.'Z.lJ who reported that 10 of 23 (43%) evaluable WiW mice were engraftable for 2 6 months. Because W/W mice are severely anemic due to stem-cell deficiency, it is possible that the engrafted cells seen in these severely anemic mice were not HSCs but long-lived committed hematopoietic progenitor cells that were at a competitive proliferative advantage as compared with the endogenous recipient HSCs. As transient engraftment has been reported especially in mildly anemic (eg, W i W " ) fetal recipients injected in utero with hematopoietic progenitors,"~"~".'~ committed progenitor cells may be responsible for early engraftment, or HSCs may become clonally lost or dormant. Although the persistence of engraftment for greater than 4 to S months is more consistent with HSC engraftment rather than the engraftment of committed multilineage progenitor cells, presumably with self-renewing properties,"'" the definition of HSCs is based not only on the capacity of these cells to provide primary multilineage reconstitution, but on their self-renewing capacity in secondary recipients. Therefore, our studies in which lethally irradiated secondary recipients were reconstituted with BM obtained from primary recipients of in utero BM at least IS0 days earlier provide the first formal evidence that murine congeneic HSCs are engraftable in utero.
Because the severity of the endogenous stem cell defect has been shown to correlate with the ability of murine hematopoietic progenitor cells to engraft, W4'/W4' fetal recipients served as a more rigorous test of in utero HSC engraftment than other anemic strains used for in utero experiments, including the W/W, W W , or WW (listed in decreasing order of severity)." Despite the more moderate anemia present in W"/WJ' recipients, we were able to achieve longterm (? 141 days) engraftment of congeneic HSCs in 50% of live-born WJ'/W3' mice injected IP. These data are in contrast with our previous studies, in which transplacental injections of congeneic adult BM lead to transient engraftment of only 0.7% ( I of 146) of nonanemic C57RL/6 fetal recipients and slightly exceed the 40% day S and 33% day 42 engraftment levels we had reported with the more severely anemic W'iW' recipients. Because the severity of anemia in WJ'/W4' mice is classified as moderate" and is much less profound than that observed in W/W mice, the most relevant comparison of our results to literature reports are studies in which W'/W' mice, also classified as moderately anemic,I5 have been used as recipients for in utero transfer experiments. Other investigators have obtained no or only a low incidence of engraftment in W'/W'mice. None of the 183 mice injected with histocompatible or histoincompatible adult BM and only 4%" to 5%"" of mice injected with fetal liver cells had any evidence of donor cell engraftment. Only the more severely anemic W/W' mice engrafted had an engraftment level comparable with that observed in our studies (44% v 50%. respectively).'' Because we used nonenriched adult BM cells, which probably contain fewer HSCs than fetal liver cells, as a progenitor source, we speculated that we should have observed a lower level of engraftment in utero in these more moderately anemic fetal recipients than was actually shown. For example, Fleishman and Mintz observed a 67% engraftment rate in W/W mice reconstituted with fetal liver cellsI3 as compared with the 35% engraftment rate observed in W/W mice reconstituted with BM cells." The 47% live-birth rate observed in our present series is comparable with our previous results of day I 1 transplacental injections [live-birth rate of 43% (S93 of 1,382 injected fetal recipients)]. The engraftment rate is at least comparable with that achieved by our group previously using the more severely anemic W"/W" mice and appears to be superior to results obtained by other investigators who have used W'N' fetal recipients. We believe that the apparently superior engraftment results we have achieved is due, at least in part, to our use of intraperitoneal injections rather than the more uncertain, and perhaps variably effective, transplacental injection technique.
An important point to discuss is the stability of engraftment of in utero transferred cells. The engraftment that was achieved in the primary and secondary recipients increased over the time period between postnatal days 39 and 141 ( Table 2) . Examination of central (thymus, BM) and peripheral (spleen, lymph node, PB) organs did not show that there was an unusual distribution of lymphohematopoietic cells, despite the fact that adult BM was injected IP during the time period of gestation in which extramedullary sites are the predominant contributors to hematopoiesis and that the cytokine production capacity of the fetus may be more supportive of endogenous fetal liver hematopoietic progenitor cells than adult BM cells." Thus, during gestation, HSCs and/or their progenitors are capable of residing in the fetal microenvironment, proliferating in the BM, and reconstituting the peripheral organs. Comixture experiments have indicated that individual progenitor cell types with multilineage reconstituting capacity can be seeded in utero by transplacental injections.'" Data in nonirradiated neonatal W/W' mice injected with small numbers of retrovirally marked cells") or in W'/W' mice injected in utero with fetal liver cells2* indicate that single multilineage progenitor cells can be For personal use only. on October 27, 2017. by guest www.bloodjournal.org From The same recipients of secondary BMTs that were evaluated for erythroid engraftment in Table 4 were analyzed for leukocyte engraftment. Two-color flow cytometry was performed on all surviving mice (n = 8 at each time period shown). The overall incidence and range of engraftment was similar in each of the secondary recipients, regardless of which donor BM these mice received. Therefore, the data are shown together for all secondary recipients.
Abbreviation: ND, not determined; NA, not analyzable. *The T-cell compartment was assessed by combining anti-CD4 and anti-CD8 antibodies without attempt to distinguish CD4' v CD8' T cells. By secondary transfer studies, we estimate the true HSC engraftment level to be 10% to 16%, consistent with the mean proportion of donor cells comprising the B-cell (10%) or granulocyte (26%) but not T-cell (42%) compartment. We are unsure if the lower level of engraftment present in the secondary as compared with the primary recipients was a function of the number of stem cells engrafted, proliferative stress induced on the stem cells in the secondary recipients, or the choice of lethally irradiated rather than nonirradiated W4'/W4' secondary recipients. Our lineage-restricted reconstitution results may parallel those we typically observe in lymphoid deficiency states, such as severe combined immunodeficiency syndrome in children who experience preferential T-cell but not B-cell, monocyte, or granulocyte engraftment. 35 Ikuta and W e i~s m a n~~ have shown that a day-l3 fetus has approximately 3 X lo6 liver hematopoietic cells, of which 0.025% (750) are putative HSCs, based on phen~typing.~~ Based on this initial phenotypic definition of HSC, the HSC content of adult BM is estimated to be 500 per lo6 cell^.'^ As we administered 1.5 X lo6 (750 HSCs), we would have anticipated a maximum donor HSC engraftment level of 50% in fetal recipients if all adult BM cells were actually delivered to the fetus and capable of engrafting. Our data of 10% to 15% donor HSCs are well within the limits of these theoretical calculations and suggest that at least 20% to 25% of adult BM cells are capable of engrafting in utero through an intraperitoneal injection route. In fact, recent evidence is more consistent with a lower HSC content in adult BM with an estimated 14 HSC/106 cells.'' Thus, as few as approximately 21 HSCs may have been injected in utero. As the level of erythroid engraftment exceeded 50% in all mice at each time period 2 2 months postnatally, these data are consistent with a more rapid and complete replacement of erythrocytes than of other lineages, due to the relative absence of selective pressure in nonerythroid lineage^^'^^^^'^ rather than reflecting the actual proportions of donor HSCs engraftable. Our data in general are consistent with the degree of erythroid reconstitution of W4'TW4' adult mice, in which 40% to 50% donor hemoglobin type was detectable 16 to 21 weeks after the injection of 7 X lo6 adult C57BW 6-+/+ BM cells.39 To achieve a higher level of stem-cell engraftment, especially in nonanemic mice, HSC-enriched p o p~l a t i o n s~~~~ and potentially more desirable sources of HSCs in utero (eg, fetal liver cells)3' will be required.
We have shown for the first time, by serial transfer studies, that true HSCs are engraftable in utero in moderately anemic mice injected IP at midgestation with nonenriched adult BM progenitor cells. Engraftment in the primary recipients was multilineage, occurring in the erythroid, T-cell, granulocyte, and B-cell lineages (listed in order of highest levels), and increased over time. The levels of engraftment achieved by the intraperitoneal route were comparable with or superior to those reported in previous studies with the transplacental route of administration. These studies lay the foundation for future attempts to cure mice with hereditary disease typically correctable by postnatal BMT.
